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The aim of the studies described in this thesis was to elucidate immunological mechanisms 
that influence the therapeutic efficacy of immunization based on recombinant Semliki Forest 
virus replicon particles (rSFV). This knowledge will contribute to the design of optimized 
protocols for the immunotherapeutic strategies against cancer using rSFV.  
In this introduction, first the role of human papillomavirus in cervical cancer development 
will be described, followed by treatment options for cervical malignancies. Next, general as-
pects of immunotherapy and different antigen delivery systems, including alphaviral vectors 
and cervical cancer immunotherapy will be introduced. Finally, tumor-dependent immuno-
suppression and methods to overcome it will be discussed.  
2. Cervical cancer and human papillomavirus infection
Cervical cancer, the second most common cancer among women worldwide, is an important 
health problem.1 The majority of cervical cancer cases (approx. 80%) is being diagnosed in 
developing countries of Africa, Central- and South Americas and Asia. The number of new 
cases diagnosed annually is estimated at 500.000; of these women 250.000 die.2 In the Neth-
erlands 600-700 women are diagnosed with cervical cancer annually and 200-250 patients die 
from this disease.2 All cervical cancer cases are associated with persistent human papillomavi-
rus (HPV) infection. Although among the majority of women HPV infections are resolved 
within months to years, persistent infections can lead to cervical cancer.1,3,4
HPV, which is a small nonenveloped icosahedral virus, belongs to the family of Papova-
viridae. It contains a double-stranded DNA genome, which encodes 6 early (E1, E2, E4, E5, 
E6 and E7) and 2 late genes (L1 and L2).5 Early genes are required for DNA replication and 
cellular transformation and late genes encode capsid proteins. Although, more than 100 HPV 
types have been identified, 4 high-risk HPV types (16,18,31 and 45) are responsible for ap-
proximately 80% of all cervical cancer cases worldwide.6 Among them, HPV16 is found in 
50% of all cervical cancers and HPV18 is present in approx. 20% of the cases.7 HPV infects 
keratinocytes of the basal epithelial layer of the cervix, which occurs via microtraumas of the 
overlying epithelial layers. In the first, maintenance, phase viral proteins are expressed at very 
low levels in undifferentiated cells (about 100 episomal copies per cell).8 This contributes to 
immune evasion and persistence of the viral infection.3 Later, viral DNA is replicated and 
virus genomes are distributed to the two daughters cells. The production of viral proteins is 
being increased once HPV-infected cells leave the basal layer.3 The restriction of high levels of 
viral protein synthesis to highly differentiated layers limits the expression of viral antigens to 
locations less susceptible to host immune surveillance.3,9 During the differentiation phase, the 
virus copy-number may amount to several thousands per cell.10 Afterwards, the virus capsid 
proteins L1 and L2 are produced and virions are assembled, which are shed into the environ-
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ment from desquamated cells in the absence of lysis or necrosis.3 Lack of danger signal (no 
inflammation) further contributes to virus persistence.11 
High expression of E6 and E7 by HPV-infected epithelial cells is crucial for cellular trans-
formation and cervical cancer development.3,5,12,13 Transformed cervical epithelial cells survive 
and become malignant only if the genes for the E6 and E7 proteins are integrated in the host 
cell chromosome and remain constantly over-expressed.14 These early proteins are critical for 
the induction and maintenance of cellular transformation in HPV-infected cells by interfer-
ing with normal function of tumor suppressor genes, notably p53 and retinoblastoma protein 
(pRb).3 The function of pRb in cell cycle regulation is inhibited by E7, which allows HPV to 
replicate in differentiating epithelial cells that would have normally withdrawn from the cell 
division cycle.15-17 This strong inhibition of pRb function by E7 increases p53 stabilization 
which under normal conditions would lead to apoptosis. However, one of the most important 
functions of E6 is the inhibition of apoptosis of HPV-infected cells by binding to p53.17,18
Since, the role of high-risk HPV E6 and E7 is so critical for cancer development, it is not 
possible for HPV-transformed cells to escape immune attack through the loss of these an-
tigens.19 Moreover, the E6 and E7 proteins are non-self, which makes the immune response 
against cells expressing these proteins very specific. Therefore E6 and E7 are potential targets 
for therapeutic immunization against cervical cancer.20
3. Prevention and current treatment of cervical cancer
Screening programs using Papanicolaou (Pap) smear test are efficient in detecting premalignant 
cervical lesions and cervical cancer at an early stage. However, no effective screening programs 
exist in developing countries and in developed countries at a maximum 70% of women partici-
pate in the screening programs.21 Since cervical cancer is caused by a virus (HPV), prevention 
of cervical cancer can be achieved via prophylactic vaccination against HPV infection.22
The discovery that HPV L1 capsid protein can be expressed in eukaryotic cells and self-
assembles into so-called virus-like particles (VLPs) was a critical step in the development of 
prophylactic HPV vaccines.23 Indeed, recombinant VLPs constitute the basic immunogens 
for the current prophylactic HPV vaccines.24,25 To date, two prophylactic vaccines [Gardasil® 
(Merck) and Cervarix® (GlaxoSmithKline)] against the high-risk types HPV16 and 18 have 
been approved. These vaccines act by blocking initial infection through induction of virus-
neutralizing antibodies. The vaccines thus protect against development of high-grade cervical 
intraepithelial neoplasia (CIN) and adenocarcinoma in situ (AIS) associated with the HPV 
types targeted by the vaccines.26-28 However, they are unable to clear existing HPV infections 
which can still cause cervical neoplasias and cancer.25 Moreover, the maximal length of protec-
tion induced by current HPV prophylactic vaccines is not known.22 Therefore it is still very 
important to continue Pap screening and to develop additional therapeutic strategies to treat 
already HPV-infected patients, who have developed (pre)malignant cervical lesions.
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The standard treatment of cervical cancer, depending on the stage of disease, consist of 
surgery, radio- and/or chemotherapy.29-33 All of these options are invasive and not specific 
enough, as healthy tissues can also be influenced by the treatments. Since, the clearance of a 
naturally acquired HPV infection is associated with specific cell-mediated immunity, immu-
notherapy is considered a feasible, more specific treatment strategy against cervical cancer or 
premalignant cervical disease.34,35
4. Immunotherapy of cervical cancer
4.1 General concepts of cancer immunotherapy
Immunotherapy of cancer, in general, aims to stimulate the immune system to reject and 
destroy tumors. It can be divided into active immunotherapy, which stimulates anti-tumor 
responses of the host through immunization or cytokine administration and passive immu-
notherapy, where for example pre-induced tumor-specific T cells or antibodies are transferred 
into host. Here, only the active immunotherapy will be presented. Active immunotherapy is 
not a new treatment method, as already in 1893, William B. Coley found that injection of 
cancer patients with live streptococcal bacteria sometimes caused the tumors to shrink and 
disappear.36 In this study live streptococcal bacteria were used as “a delivery vector”. It has to be 
mentioned that in this particular case induction of innate immunity cleared the tumor, where-
as in the immunotherapeutic strategies described below adaptive immune responses (mainly 
based on T cells) are induced. Nowadays, the vectors which are being used are certainly of 
higher purity and safer than live streptococcal bacteria. However, it is still very challenging to 
deliver antigen in such a form that it will induce effective immune responses which will result 
in tumor clearance. 
Different immunotherapeutic strategies to induce an anti-tumor immune response include 
immunization with synthetic peptides, recombinant proteins, plasmid DNA, autologous den-
dritic cells or bacterial or recombinant viral vectors. Most of these vectors have already been 
tested in cervical cancer models.20 Viral vector-based vaccines have the advantage, in com-
parison with other vectors, that the entire tumor antigen can be incorporated in the viral 
vector. This enables the induction of a broad immune response, since T cells against differ-
ent antigen epitopes are induced. Among the viral vectors employed, adenoviral vectors are 
most commonly used in human clinical studies.37 The potency of adenoviral vectors has been 
evaluated in a variety of diseases.38 Adenoviral vectors have proven to be safe and allow inser-
tion of relatively large foreign genes. However, since adenoviruses are responsible for 5-10% 
of upper respiratory infections in children and many infections in adults as well, antibodies 
against these viruses are broadly present in humans.39 These antibodies can suppress immune 
responses induced by adenoviral vectors. Moreover, some concerns were raised about the use 
of adenovirus-based vectors after a fatal case of systemic inflammation following adenoviral 
gene transfer.40,41 Therefore, it is of great interest to identify and exploit other viral vectors, 
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which can induce efficient immune responses in cancer patients. Alternative candidates are, 
amongst others, alphaviral vectors, which are gaining increasing interest lately.
4.2 Immunotherapy of cervical cancer based on recombinant Semliki Forest virus 
         replicon particles 
Alphaviruses are small, enveloped, positive-strand RNA viruses belonging to the family Toga-
viridae. Among all alphaviruses, Semliki Forest virus (SFV), Venezuelan Equine Encephalities 
virus (VEE) and Sindbis virus (SIN) are most frequently used as delivery vectors. These vec-
tors have been developed in the late 80s and early 90s by different groups.42-45 
The recombinant SFV replicon expression system (rSFV) has been initially developed by 
Liljestrom and Garoff.43 The production of rSFV starts from cloning of a full-lenght cDNA 
copy of the SFV genome into the bacterial plasmid. Since this infectious clone contains a 
prokaryotic DNA-dependent RNA polymerase, the viral RNA can be transcribed in vitro. 
These RNA transcripts are fully infectious, i.e. introduction into cells suffices to initiate rep-
lication and full infection cycle, resulting in virus formation.46 Recombinant SFV particles 
Figure 1. Recombinant SFV vector and two helper vectors
Recombinant SFV encodes for 4 non-structural proteins (nsP1-nsP4) and the antigen of interest. Non-struc-
tural proteins form viral replicase. Helper vector encodes for capsid and spike proteins which are needed for 
assembly of recombinant virus particles. To increase safety in humans split-helper vector can be used. See 
text for more details. 
encoding a gene of interest can be generated by co-transfection of cells with recombinant SFV 
RNA and helper SFV RNA. Recombinant SFV RNA codes for the gene of interest and helper 
SFV RNA codes for the structural (capsid and spike) proteins, which are necessary for assem-
bly of rSFV particles (Figure 1). When introduced into cells these RNAs are amplified and 
translated (Figure 2). Since the packaging signal is located on the recombinant SFV RNA, 
only this RNA is being packed into newly formed rSFV particles. Therefore, rSFV particles 
can undergo only one round of infection because they do not contain RNA encoding the 
structural proteins of the virus. This type of recombinant virus particles is called “suicide par
14  |  CHAPTER 1 GENERAL INTRODUCTION  |  15
 
ticles”. The split helper SFV RNA can offer increased biosafety in humans. This system consist 
of two helper SFV RNAs: one encoding for the capsid protein and the other for the spike 
proteins.47 This modification even further decreases the probability of formation of infectious 
replication-competent virus. Additionally, the expression of the gene of interest in the rSFV 
particles can be enhanced by the incorporation of a translational enhancer element.48 
After immunization, rSFV particles infect a broad range of host cells, which undergo apop-
tosis (Figure 3).49 This results in the formation of apoptotic bodies, filled with antigen, which 
are taken up by antigen-presenting cells (APCs). Next, APCs cross-present the antigen to CD8 
and CD4 T cells resulting in the induction of antigen-specific immune responses.50,51
Immunizations based on rSFV replicon particles are characterized by a high transfection 
potency and strong immunogenicity.46,52 Recombinant SFV replicon particles have been used 
as experimental vaccines to induce protective and therapeutic immune responses against vi-
ruses in animal models including influenza, human immunodeficiency and respiratory syn-
cytial virus.53-55 Furthermore, rSFV also induces effective anti-tumor responses in different 
animal models.52 We are evaluating the use of rSFV encoding a fusion protein of E6 and E7 
from HPV type 16 (SFVeE6,7), as a potential candidate for therapeutic immunization against 
HPV-induced cervical cancer. We have demonstrated that immunization with SFVeE6,7 par-
ticles results in strong HPV-specific cellular responses and eradication of established HPV-
Figure 2. Production of recombinant SFV.
Recombinant SFV RNA (encoding for the replicase complex and antigen of interest) and SFV helper RNA 
(encoding for capsid and spike proteins) are co-electroporated into the cell. After introduction to the cell, 
recombinant SFV RNA is being self-replicated resulting in high levels of RNA encoding for antigen of 
interest. Since the packaging signal is present on recombinant SFV RNA, only this RNA is packed into 
newly formed capsids (produced after translation of SFV helper RNA). It prevents formation of infectious 
replication-competent virus. Finally, recombinant SFV RNA associated with capsid travels to the cellular 
membrane and assembles with spike proteins (produced after translation of SFV helper RNA). It results in 
the formation of recombinant virus particles which are released from the cell
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transformed tumors.56-58 Moreover, immunization with SFVeE6,7 induces strong antitumor 
responses even in immune-tolerant mice.59
In summary, alphavirus-based vaccines, including rSFV, are efficient in inducing immune 
responses in animals models.46,52 Nevertheless, up to now, only vaccines based on VEE virus 
have been evaluated in clinical trials (www.clinicaltrials.gov). VEE virus replicon particles ap-
pear to be safe and well tolerated. Nevertheless, additional clinical evaluations with different 
alphavirus-based vaccines are necessary to further prove the potency of these vector systems.
4.3 Immunotherapy of cervical cancer based on influenza-derived virosomes
Virosomes can be used as antigen delivery system. Virosomes were first produced by Almeida 
et al. in 1975 and consisted of lipid vesicles containing viral spike proteins from influenza 
virus.60 Later, in 1987, our group described a new method to generate influenza virosomes by 
reconstitution of virus-like particles solely from viral membrane lipids and proteins.61 Viro-
somes can be generated from different viruses including Sendai virus, Rubella virus, human 
immunodeficiency virus, herpes simplex virus and hepatitis A virus.62-65 
Part of the research described in this thesis focuses on the use of influenza virus derived 
virosomes to immunize against HPV-induced cervical cancer. These virosomes contain E7 
protein from HPV16.66-68 Since, virosomes are reconstituted virus envelopes they retain the 
cell entry properties of the native virus, without being infectious.69 APCs can acquire viro-
somes via receptor-mediated endocytosis. The E7 protein encapsulated in the virosomal lu-
men may thus be introduced in the major histocompatibility complex (MHC) class I route 
of antigen presentation.70 This results in efficient induction of cytotoxic T cells which can lyse 
HPV-transformed tumor cells. Therefore influenza virosomes, next to rSFV, may be used as 
apotential therapeutic vaccine against HPV-induced cervical cancer.  
Figure 3. Proposed mechanism of antigen processing and presentation after recombinant SFV immunization
When recombinant SFV is injected into animal it can infect many different cell types. These cells undergo 
apoptosis and apoptotic bodies filled with antigen of interest (encoded by recombinant SFV)  are formed. 
Since dendritic cells (antigen presenting cells) cannot be directly infected with recombinant SFV, they ac-
quire antigen from apoptotic bodies. Next, the antigen is being processed by antigen presenting cells and 
finally presented to T cells, in the context of MHC class I and II molecules. This results in the generation of 
T cells specific for the antigen encoded by recombinant SFV. 
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4.4 Heterologous prime-boost immunization protocols
In general, immunization procedures can be divided into homologous and heterologous pro-
tocols. In homologous prime-boost immunization protocols the same delivery vector is used 
in the prime and boost immunization. On the other hand, in heterologous prime-boost im-
munization strategies, an antigen-specific immune response is primed by delivery of the target 
antigen by one vector and selectively boosted by a subsequent immunization using a second, 
distinct, vector.71-74 Heterologous prime-boost protocols are generally thought to be more ef-
fective than homologous protocols in inducing immune responses.74-77
Avoiding humoral and/or cellular vector-specific immunity most likely explains the higher 
efficacy of heterologous prime-boost-protocols compared to homologous protocols.71-74 An-
tibodies, induced by the prime immunization, may neutralize the vector or antigen delivery 
system, during the booster immunization. It is also possible that, during the prime immuniza-
tion, T lymphocyte responses against epitopes of both the target antigen and the vector system 
are induced. In homologous prime-boost protocols, both of these responses will be stimulated 
by the booster immunization. A heterologous booster only shares the target antigen with the 
priming immunization and will therefore preferentially boost the T lymphocyte response 
against the target antigen. Heterologous prime-boost protocols thereby focus the immune re-
sponse on epitopes of the target antigen.74,77-79 
4.5 Innovative methods of vaccine administration into the skin
Intramuscular or subcutaneous injection is the most common method of immunization. Since 
skin contains more antigen-presenting cells (APCs) than muscle and subcutaneous tissue, it 
seems that skin can be a better place to trigger immune response than these other two sites.
Antigen/vector can be administered into the skin via transcutaneous or intradermal im-
munization. In transcutaneous immunization, antigen is delivered into the epidermis and/or 
dermis through intact or pre-treated skin.80 Smallpox immunization in humans is a successful 
example of transcutaneous vaccination.80 The main obstacle for transcutaneous immunization 
is the very limited transport of antigens across the stratum corneum, the uppermost layer of 
the skin. Therefore, physical methods are utilized to overcome the stratum barrier.80 These 
methods comprise the use of a large variety of microneedle arrays, skin abrasion, low frequency 
ultrasound, electroporation, thermo-ablation and jet immunization.81-86 
By intradermal immunization, antigen is delivered into the dermis. Intradermal injection 
was invented in the early 1900s and it is up to date the most frequently used method of intra-
dermal immunization.80 It has been shown that hepatitis B-, influenza- and therapeutic cancer 
vaccines can be safely and efficiently delivered via intradermal injection. Moreover, stronger 
immune responses with a lower antigen dose compared to intramuscular or subcutaneous in-
jection were observed.87,88 However, traditional intradermal injection requires well-trained 
healthcare workers. Therefore new devices for intradermal injection are being developed.89,90 
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One of the promising alternative methods of antigen delivery into the skin, as shown for DNA-
based immunizations, can be tattoo injection. Conventional DNA vaccines elicited higher 
cellular immune responses in mice and non-human primates, when delivered with a tattoo 
device compared to an intramuscular injection.91-93 Yet, little is known about the efficacy of 
other vectors delivered by tattoo injection.
5. Challenges in immunotherapy
Several mechanisms including production of suppressive cytokines, downregulation of MHC 
class I molecules, attraction and activation of immunosuppressive cells (such as regulatory T 
cells and/or myeloid-derived suppressor cells) and activation of negative costimulatory signals 
can be responsible for escape of tumors from immune attack.94-96 Moreover, tumor cells often 
do not secrete danger signal molecules since they originate from naïve cells. As a result, APCs 
presenting tumor antigens are not properly activated and induce T cell tolerance towards 
tumors.95,97,98 All of these processes are potential obstacles for effective cancer immunotherapy. 
Selected aspects of tumor-dependent immunesuppression and some methods to overcome it 
are described below.
5.1 Immunosuppressive cells 
Regulatory T cells (Treg) are known as key mediators of immune responses to self and non-
self antigens.99-101 Treg develop in the thymus or are generated in the periphery and generally 
co-express some of the cellular markers such as: CD4, CD25, CTLA4 and/or GITR.102,103 
The transcription factor Foxp3 is one of the key controllers of Treg development and its ex-
pression is essential to establish a functional regulatory T cell lineage.104-108 Treg may use mul-
tiple mechanisms to suppress immune responses including secretion of immunosuppressive 
cytokines (e.g. IL-10, TGFb, IL-35), cytotoxicity or inhibition of dendritic cell maturation 
and function.109-111  
Treg are essential to maintain immune homeostasis and prevent autoimmunity.99-101 Yet, 
because of their immune suppressive activity, Treg may also dampen immune responses that are 
meant to be elicited with immunotherapeutic vaccines. To overcome this caveat and enhance 
immune responses, depletion of regulatory T cells is implied to be used in immunotherapies.112-
118 Although CD25 is also expressed on activated T cells, anti-CD25 antibody is still one of 
the most commonly used strategies to deplete Treg in mouse studies.112,114 An alternative op-
tion for anti-CD25 is to use cyclophosphamide. Treatment with low-doses of cyclophosph-
amide resulted in Treg depletion and enhanced immune response and augmented anti-tumor 
immunity.115,117,118 However, the concomitant reduction of B cells and CD8 T cells can be a 
major limitation for broad use of cyclophosphamide.119,120 Moreover, cyclophosphamide ac-
celeration or potentiation of experimental autoimmunity has been described in a number of 
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experimental systems.121,122 These observations indicate a need for more selective agents to de-
plete/inactivate Treg.
Myeloid-derived suppressor cells (MDSCs), next to Treg, are regulators of immune re-
sponses. They represent a heterogenic population of immature myeloid cells.123 Murine MD-
SCs are characterized by the expression of CD11b and Gr-1 markers.123 In humans, it is more 
difficult to characterize MDSCs. They are usually defined as cells expressing CD33 but lacking 
markers of mature myeloid and lymphoid cells.124 Elevated MDSCs levels have been detected 
in many different cancers including melanoma, colon, lung and renal cell cancer.125-130 These 
cells are characterized by a strong ability to suppress various T cell functions.123,131 The main 
mechanisms of MDSC suppression include induction of high levels of nitric oxide, reactive 
oxygen species and arginase activity.123,132-134 Interestingly, it has also been shown that MDSCs 
can induce regulatory T cells.135-137 Since, MDSCs contribute to the failure of immunothera-
pies in patients with advanced cancer and in tumor-bearing mice, depletion and/or inactiva-
tion of these cells can improve treatment outcome. Different strategies for therapeutic target-
ing of MDSCs are currently being investigated including all-trans retinoic acid, vitamin D3, 
anti-VEGF antibody and Sunitinib.131,138-140 All of these results indicate that immunotherapy 
of cervical cancer could be improved by combining with immunosuppressive cells (Treg and/
or MDSCs) depletion/inactivation protocols.
5.2 Lack of efficient CTL homing
Efficient homing of specific T cells to the tumor is one of the important requirements for 
effective immunotherapy. T cells trafficking to a tumor depends on a match between chemok-
ines produced by the tumor cells and their receptors on T cells.141,142 Activated CD8 T cells 
express CCR2, CCR5 and CXCR3.143 Many human tumors, including cervical tumors, pro-
duce low levels of chemokines or secrete these chemokines for which T cells lack receptors. 
For example, Gro-α is produced by a large percentage of melanomas but its receptor, CXCR2, 
is expressed only on a small subset of T cells.144,145 Therefore, specific T cells may have problems 
sensing a tumor.
Lack of efficient specific T cells trafficking to the tumor is one of the major obsta-
cles for T-cell-based immunotherapies.142 Therefore strategies to promote T cell recruit-
ment to the tumor can improve immunotherapies. It has been shown that upregulation of 
chemokine T cell receptors, such as CXCR2, CCR2b or CCR4, enhance their migration 
to the tumor sites.142,146,147 Furthermore, transduction of tumor cells (using viral vectors) 
to express specific chemokines improve treatment outcome in some experimental murine 
models.148-152
Another experimental approach to improve T cell trafficking to the tumor is based on 
an attempt to transform tumor microvessels into high endothelial venules (HEV)-like ves-
sels that support recruitment of immune effector cells. Secondary lymphoid organs, which 
are portals for efficient trafficking of naïve and central memory T cells are characterized by 
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high-walled HEV-like vessels. In contrast, flat-walled vessels at intratumoral sites do not ex-
press high levels of hallmark trafficking molecules such as intercellular adhesion molecule-1 
(ICAM-1) or vascular cell adhesion molecule-1 (VCAM-1). It has been shown that adminis-
tration of CpG motifs into mice induces ICAM-1 and VCAM-1 expression on intratumoral 
vessels.153 Moreover, strong antitumoral infiltration of tumor-specific CD4 and CD8 T cells 
has been observed, when CpG administration was combined with adoptive transfer. 
Direct damage to tissues in the tumor microenvironment can cause an acute inflamma-
tory response, accompanied by massive release of proinflamatory cytokines, which can attract 
T cells to the tumor tissue. Ionizing radiation (IR) can be used to induce localized tissue dam-
age in the tumor microenvironment. Tumors isolated from irradiated mice were highly in-
filtrated with CD8 T cells.154-156 This was accompanied by the upregulation of chemokines 
(CXCL9 and CXCL10) and adhesion molecules such as VCAM-1 or ICAM-1 on tumor 
microvessels. Therefore, local radiation could be used in combination with immunotherapy of 
cervical cancer to increase specific T cell homing to the tumor.   
6. Outline of this thesis
Chapter 2 presents a comparative study of the efficacy of rSFV and an adenovirus-based vec-
tor in inducing anti-tumor responses in a mouse model of cervical cancer. The differences in 
gene expression levels and CTL responses after immunization with both vectors were investi-
gated. Furthermore, effects of CD4 and CD8 T cell depletion on the efficacy of both vectors 
were studied.
Chapter 3 describes an immunization study using rSFV and virosomes in a heterologous 
prime-boost setup. It was investigated, whether heterologous prime-boosting with virosomes 
and rSFV is able to induce more potent immune responses than homologous prime-boost pro-
tocols. Furthermore, the role of regulatory T cells, different subsets of CD8 T cells and vector-
specific immunity on the efficacy of heterologous prime-boost protocols was evaluated.
Chapter 4 investigates the efficacy of rSFV administered via tattoo injection, an innovative 
method of antigen delivery into the skin. It is the first study describing skin tattooing using 
a recombinant alphavirus-based vector. The efficacy of rSFV tattoo was compared to rSFV 
intramuscular injection. The differences in gene expression levels and CTL responses were 
investigated. In addition, anti-tumor therapeutic response and induction of memory T cells 
with rSFV tattoo injection were evaluated.
Chapter 5 investigates the role of regulatory T cells (Treg) on the efficacy of rSFV immuniza-
tions. Changes in Treg levels after rSFV immunizations were studied. Furthermore, the effect 
of Treg depletion on the therapeutic efficacy of rSFV in tumor model was evaluated. The nov-
el, very efficient, antibody (anti-folate receptor 4 antibody) was used to deplete Treg in vivo. 
Chapter 6 describes the role of local tumor radiation on efficacy of T cell homing into the tu-
mor tissue. Labeling of specific T cells with an intracellular fluorescent dye allowed tracking 
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of these cells.
Chapter 7 presents a discussion of the research described in this thesis. In addition it provides 
future perspectives on the use of rSFV in immunotherapeutic strategies.
Chapter 8 summarizes this thesis.  
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